Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060514 · ClinicalTrials.gov registry record · Phase 1
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
A Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01060514: Clinical Trial Phase 1 study, sponsored by Northwestern University.
NCT01060514 is a Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01060514, a Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects. Also, this study will evaluate what effects (good and bad) that the treatment has on patients and their cancer.
Interventions
- DRUG Vinorelbine
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Why NCT01060514 stopped before completion
NCT01060514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Vinorelbine is the first listed.
NCT01060514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01060514 about?
NCT01060514 is a clinical study titled "Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer". The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that can be given together without causing severe side effects. Also, this study will evaluate what effects (good and bad) that the treatment has on patients and their cancer.
What is the current status of trial NCT01060514?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2010-02. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01060514?
The interventions under investigation include: Vinorelbine (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT01060514?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01060514's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia